KRON - Kronos Bio: Underestimated Drug Discovery Platform

2024-05-06 18:40:11 ET

Summary

• Kronos Bio, Inc.'s drug discovery platform has a lot of potential in targeting transcription regulatory networks. Genetech collaboration validates big pharma interest.
• KB-0742, Kronos Bio's lead asset, is an orally bioavailable highly selective CDK9 inhibitor that has demonstrated promising single-agent antitumor activity and tolerability in an ongoing ph1/2 study.
• Kronos Bio will present an update in ASCO (01 June 2024). Top-line results are expected in 1H 2025.
• KB-9558, Kronos Bio's second internally developed asset, has demonstrated promising preclinical activity against multiple myeloma. Kronos plans initiation of a first-in-human trial in 1H 2025.

Thesis overview

Kronos Bio, Inc. ( KRON ) is an early clinical stage biotech targeting dysregulated transcription pathways in cancer. KRON's discovery platform aims to identify optimal targets within transcription regulatory networks to suppress oncogenic activity while avoiding (to the extent possible) off-target gene expression dysregulation.

KRON currently has only one clinical-stage candidate (in phase 1/2 stage), KB-0742, an orally bioavailable selective CDK9 inhibitor being developed for MYC-amplified and other transcriptionally addicted tumors. KRON's second asset, KB-9558, is being developed for multiple myeloma and initiation of the first trial in humans is planned 1H 2025. KRON is also developing additional undisclosed assets, all in the preclinical stage, including a preclinical collaboration with Genentech....

For further details see: